Physicians' Academy for Cardiovascular Education

Somatostatin concentrations associated with increased risk of CVD and mortality

Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study

Abbasi A, Kieneker LM, Eva Corpeleijn E, et al. - Clinical Chemistry 2017;63(1): 278–287


Somatostatin, present in many tissues, plays an important role in neuroendocrine regulation through: inhibition of growth hormone (GH)7 release from the pituitary gland [1], inhibition of glucagon secretion and suppression of the release of insulin-like growth factor-1 (IGF-1) that has been associated with CV outcomes [2], inhibition of several hormones, including serotonin, vasoactive intestinal polypeptide (VIP), gastrin, insulin, glucagon, secretin, and motilin [3], and regulatory effects on the gastrointestinal tract, the endocrine pancreas, the immune system, and the CV system [4].

The N-terminal fragment prosomatostatin 1–64 (NT-proSST) is a stable fragment of endogenous somatostatin precursor and reflects somatostatin concentrations and may be a marker for acute HF and mortality [5].

This study evaluated the associations of plasma NT-proSST with incident CVD and all-cause mortality in participants without a history of CVD at baseline (aged 28-75 years), from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study. Furthermore, the predictive value of NT-proSST when added to the Framingham Risk Score (FRS) was assessed in this population.

Main results


NT-proSST concentrations were associated with an increased risk of incident CVD and all-cause mortality, after adjusting for traditional CVD risk factors and emerging biomarkers, in a population-based cohort of men and women without a history of CVD. These findings support a possible future predictive role of NT-proSST concentrations.


Show references

Find this article online at Clinical Chemistry